ALAS1 and cholangiocarcinoma: ECH1, MALT1, and ALAS1 were the top 3 perturbagen gene candidates by analysis of the gene signatures in LINCS dataset since their expression was affected by regorafenib treatment in all three CCA cell lines (Supplementary Table 1).